Solventum has announced a major move in the advanced wound care space with a definitive agreement to acquire Acera Surgical for $725 million in cash, plus an additional $125 million in contingent payments tied to milestone achievements.
The acquisition marks Solventum’s first tuck-in deal as part of its broader transformation strategy—and positions the company to expand aggressively into the fast-growing regenerative wound care market.
Founded in 2013, Acera Surgical has built a strong reputation in synthetic soft-tissue repair through its proprietary electrospinning technology platform. Its flagship Restrata products are already used across U.S. acute care settings to treat complex, hard-to-heal wounds.
The acquisition brings together:
Together, the companies expect to accelerate the adoption of Restrata and unlock new synergies across Solventum’s global network.
Solventum CEO Bryan Hanson emphasized that regenerative wound care is a high-growth market with a major unmet need:
“Regenerative wound care is an exciting and fast-growing space, and Acera has innovative technology to meet a significant unmet need in acute wound care.”
He added that the deal:
Hanson also highlighted that Solventum’s strong balance sheet enabled the company to move decisively—alongside announcing its first share repurchase program.
The combination is expected to unlock operational and commercial synergies by leveraging:
Solventum is aiming to strengthen its position at the intersection of:
Acera’s engineered tissue platforms fit directly into that strategy.
This deal allows Solventum to:
For Solventum:
For Acera:
Solventum is a healthcare company committed to enabling better, smarter, safer care. Built on decades of scientific innovation, the company focuses on creating breakthrough solutions at the intersection of health, materials, and data science, empowering clinicians and improving patient outcomes.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!